S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
New CBOE “special perk” helps traders target income every weekend (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
New CBOE “special perk” helps traders target income every weekend (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
New CBOE “special perk” helps traders target income every weekend (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio
S&P 500   4,569.78
DOW   36,204.44
QQQ   386.32
Are penny stocks worth it? Should you invest in penny stocks?
New CBOE “special perk” helps traders target income every weekend (Ad)
Why do tech stocks go down when interest rates rise?
Own Dollar General? Hurry and take this advice before earnings
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Pure Storage stock fumbles for a rare buying opportunity
Black Swan: this small cap surged over 1000% last week
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Snowflake’s bullish tailwind is turning into a gale-force wind
2 energy drink makers to wake up your portfolio

SAB Biotherapeutics Stock Price, News & Analysis (NASDAQ:SABS)

$0.91
-0.03 (-3.19%)
(As of 12/4/2023 ET)
Compare
Today's Range
$0.88
$0.97
50-Day Range
$0.47
$1.01
52-Week Range
$0.37
$1.45
Volume
197,478 shs
Average Volume
408,146 shs
Market Capitalization
$47.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.00

SAB Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
9.9% Upside
$1.00 Price Target
Short Interest
Healthy
0.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.59mentions of SAB Biotherapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$14,290 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.46) to ($0.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.72 out of 5 stars

Medical Sector

865th out of 952 stocks

Biological Products, Except Diagnostic Industry

144th out of 155 stocks


SABS stock logo

About SAB Biotherapeutics Stock (NASDAQ:SABS)

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.

SABS Stock Price History

SABS Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
SAB Biotherapeutics GAAP EPS of -$0.10
SAB Biotherapeutics GAAP EPS of -$0.14
SAB Biotherapeutics (SABS) Gets a Buy from Chardan Capital
See More Headlines
Receive SABS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/12/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:SABS
Fax
N/A
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.00
High Stock Price Target
$1.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+9.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-18,740,000.00
Net Margins
-664.68%
Pretax Margin
-664.04%

Debt

Sales & Book Value

Annual Sales
$23.90 million
Book Value
$0.72 per share

Miscellaneous

Free Float
36,006,000
Market Cap
$47.61 million
Optionable
Not Optionable
Beta
1.03
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Samuel J. Reich (Age 48)
    Executive Chairman
    Comp: $376.2k
  • Dr. Eddie Joe Sullivan Ph.D. (Age 57)
    Co-Founder, President, CEO & Director
    Comp: $430.62k
  • Ms. Christine E. Hamilton M.B.A. (Age 67)
    Co-Founder & Independent Director
    Comp: $25k
  • Dr. Alexandra Kropotova M.B.A. (Age 50)
    M.D., Executive VP & Chief Medical Officer
    Comp: $486.96k
  • Dr. Edward D. Hamilton D.V.M.
    Co-Founder & Board Observer
  • Mr. Michael George King Jr. (Age 62)
    Chief Financial Officer
  • Dr. Christoph Bausch M.B.A. (Age 52)
    Ph.D., Executive VP & COO
  • Mr. Russell P. Beyer C.M.A. (Age 68)
    M.B.A., Senior Advisor
  • Dr. Carlos N. Carillo Ph.D.
    Senior Vice President of Regulatory Affairs














SABS Stock Analysis - Frequently Asked Questions

Should I buy or sell SAB Biotherapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SAB Biotherapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SABS shares.
View SABS analyst ratings
or view top-rated stocks.

What is SAB Biotherapeutics' stock price target for 2024?

2 brokerages have issued twelve-month price targets for SAB Biotherapeutics' shares. Their SABS share price targets range from $1.00 to $1.00. On average, they expect the company's stock price to reach $1.00 in the next year. This suggests a possible upside of 9.9% from the stock's current price.
View analysts price targets for SABS
or view top-rated stocks among Wall Street analysts.

How have SABS shares performed in 2023?

SAB Biotherapeutics' stock was trading at $0.5899 on January 1st, 2023. Since then, SABS shares have increased by 54.3% and is now trading at $0.91.
View the best growth stocks for 2023 here
.

When is SAB Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024.
View our SABS earnings forecast
.

How were SAB Biotherapeutics' earnings last quarter?

SAB Biotherapeutics, Inc. (NASDAQ:SABS) posted its quarterly earnings results on Monday, November, 13th. The company reported ($0.10) EPS for the quarter, meeting analysts' consensus estimates of ($0.10). The firm had revenue of $1.27 million for the quarter. SAB Biotherapeutics had a negative net margin of 664.68% and a negative trailing twelve-month return on equity of 120.36%.

Who are SAB Biotherapeutics' major shareholders?

SAB Biotherapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Pathstone Family Office LLC (0.97%). Insiders that own company stock include Christine E Hamilton, Michael King and Samuel J Reich.
View institutional ownership trends
.

How do I buy shares of SAB Biotherapeutics?

Shares of SABS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SABS) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -